Vontobel Holding Ltd. Buys New Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Vontobel Holding Ltd. purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 287,423 shares of the company’s stock, valued at approximately $2,584,000.

Other hedge funds have also recently made changes to their positions in the company. US Bancorp DE boosted its position in shares of Travere Therapeutics by 1,372.3% during the 1st quarter. US Bancorp DE now owns 1,487 shares of the company’s stock valued at $38,000 after purchasing an additional 1,386 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Travere Therapeutics by 968.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock worth $51,000 after buying an additional 5,121 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Travere Therapeutics by 31.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 7,929 shares of the company’s stock worth $71,000 after buying an additional 1,876 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Travere Therapeutics by 353.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock valued at $78,000 after acquiring an additional 6,773 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Travere Therapeutics by 21.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,016 shares of the company’s stock valued at $92,000 after acquiring an additional 1,074 shares during the period.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $5.80 on Friday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. The business has a fifty day simple moving average of $7.62 and a 200 day simple moving average of $7.75. Travere Therapeutics, Inc. has a 12 month low of $5.25 and a 12 month high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The company had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. As a group, equities research analysts expect that Travere Therapeutics, Inc. will post -3.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on TVTX shares. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Travere Therapeutics in a report on Wednesday, March 13th. Wedbush restated an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a research note on Wednesday. Wells Fargo & Company upped their price target on Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Friday, February 16th. Piper Sandler raised their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, January 18th. Finally, Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.85.

Insiders Place Their Bets

In other news, CEO Eric M. Dube sold 7,873 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $8.96, for a total value of $70,542.08. Following the transaction, the chief executive officer now owns 234,722 shares in the company, valued at approximately $2,103,109.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Eric M. Dube sold 7,873 shares of Travere Therapeutics stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $8.96, for a total transaction of $70,542.08. Following the sale, the chief executive officer now directly owns 234,722 shares in the company, valued at approximately $2,103,109.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric M. Dube sold 19,122 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the transaction, the chief executive officer now owns 350,600 shares of the company’s stock, valued at approximately $3,050,220. The disclosure for this sale can be found here. Insiders have sold a total of 48,030 shares of company stock valued at $419,773 in the last 90 days. 3.75% of the stock is currently owned by corporate insiders.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.